Randomised, double‑blind, crossover pharmacology study in healthy volunteers (n=16) testing reboxetine (8 mg, two doses) on subjective and cardiovascular effects of MDMA (125 mg).
This randomised, double‑blind, crossover study in 16 healthy volunteers tests whether the selective norepinephrine transporter inhibitor reboxetine attenuates the subjective and cardiovascular stimulant effects of a single oral MDMA dose (125 mg).
Reboxetine (8 mg) or placebo is given the night before and ~1 hour before each session; MDMA or placebo is administered in four counterbalanced sessions. Outcomes include repeated measures of subjective effects, heart rate, blood pressure and plasma PK. The study aims to clarify norepinephrine’s contribution to MDMA’s pharmacology.
Randomised, double-blind, crossover with four experimental sessions testing MDMA and reboxetine/placebo combinations in the same subjects.
Single oral MDMA 125 mg
Reboxetine 8 mg administered night before and ~1 h before session (two doses)
Placebo capsules identical to MDMA or reboxetine